TAS 114

Drug Profile

TAS 114

Alternative Names: TAS-114

Latest Information Update: 29 Dec 2016

Price : $50

At a glance

  • Originator Taiho Pharmaceutical
  • Class Antineoplastics
  • Mechanism of Action Dihydropyrimidine dehydrogenase inhibitors; DUTP pyrophosphatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I Solid tumours

Most Recent Events

  • 29 Nov 2016 Adverse events, efficacy and pharmacokinetics data from a phase I trial in Solid tumours (Combination therapy) presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
  • 29 Nov 2016 Adverse events, efficacy, pharmacokinetics and pharmacodynamics data from a phase I trial in Solid tumours (Combination therapy) presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
  • 01 Aug 2016 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Japan (PO) (NCT02855125)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top